Ingevity (FRA:IGX) Total Liabilities : €1,685 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Ingevity Total Liabilities?

Ingevity's Total Liabilities for the quarter that ended in Mar. 2025 was €1,685 Mil.

Ingevity's quarterly Total Liabilities declined from Sep. 2024 (€1,799.39 Mil) to Dec. 2024 (€1,745.17 Mil) and declined from Dec. 2024 (€1,745.17 Mil) to Mar. 2025 (€1,684.89 Mil).

Ingevity's annual Total Liabilities declined from Dec. 2022 (€1,924.06 Mil) to Dec. 2023 (€1,826.57 Mil) and declined from Dec. 2023 (€1,826.57 Mil) to Dec. 2024 (€1,745.17 Mil).

Ingevity Total Liabilities Historical Data

The historical data trend for Ingevity's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ingevity Total Liabilities Chart

Ingevity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,391.15

1,588.75

1,924.06

1,826.57

1,745.17

Ingevity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															1,838.80	1,850.01	1,799.39	1,745.17	1,684.89

Ingevity Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ingevity's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	252.216	+	(1314.558	+	101.706
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	68.856	+	7.831	+	0)
	=	1,745

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1931.583	-	186.416
	=	1,745

Ingevity's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	244.755	+	(1232.655	+	152.902
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	54.575	+	0	+	0)
	=	1,685

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	1901.892	-	217.005
	=	1,685

Ingevity Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ingevity's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ingevity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Ingevity Corp (FRA:IGX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NGVT:USA

Address

4920 O'Hear Avenue, Suite 400, North Charleston, SC, USA, 29405

Website

https://www.ingevity.com

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

Ingevity Headlines

No Headlines